[Pramipexole and Parkinson's disease, an update]

Area of Science:

• Neurology
• Pharmacology

Background:

• Pramipexole is a D2/D3 dopaminergic agonist used for Parkinson's disease (PD).
• It's effective in early monotherapy and advanced stages with levodopa, improving motor fluctuations and dyskinesias.
• Laboratory studies suggest neuroprotective effects, potentially delaying motor complications.

Purpose of the Study:

• To review the efficacy and safety of pramipexole in Parkinson's disease.
• To highlight its benefits for motor and non-motor symptoms, including tremors and depression.
• To compare pramipexole with ergotic dopaminergic agonists regarding side effect profiles.

Main Methods:

• Literature review of pramipexole's clinical use and effects.
• Analysis of studies on its efficacy in different PD stages.
• Comparison of adverse event profiles with ergotic agents.

Main Results:

• Pramipexole demonstrates safety and efficacy in early and advanced PD.
• It improves motor symptoms like fluctuations, dyskinesias, and tremors.
• It also benefits non-motor symptoms such as depression and has a favorable side effect profile compared to ergotic agonists.

Conclusions:

• Pramipexole is a valuable treatment option for Parkinson's disease, offering broad symptom control.
• Its non-ergotic nature provides a safer profile, minimizing severe side effects like fibrosis and valve disease.
• Further research is needed to clarify long-term effects and differentiate between non-ergotic agonists.